Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same
A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered.
1 . A fused solid dispersion comprising an active ingredient having a melting point of 80° C. or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 m 2 /g.
2 . The fused solid dispersion of claim 1 , which comprises the active ingredient and the pharmaceutically acceptable absorbent in a weight ratio ranging from 1:0.01 to 1:3.
3 . The fused solid dispersion of claim 1 , wherein the active ingredient having a melting point of 80° C. or below is ibuprofen, dexibuprofen (S(+)-ibuprofen) or a mixture thereof.
4 . The fused solid dispersion of claim 1 , which further comprises a tabletting aid selected from the group consisting of a sugar alcohol, a water soluble polymer, an oily base and a mixture thereof.
5 . The fused solid dispersion of claim 4 , which comprises the active ingredient and the tabletting aid in a weight ratio ranging 1:0 to 1:2.
6 . The fused solid dispersion of claim 1 , wherein the pharmaceutically acceptable absorbent is selected from the group consisting of light anhydrous silicic acid, hydrotalcite, aluminum magnesium silicate, aluminum hydroxide, aluminum silicate, magnesium aluminum methasilicate, bentonite, lactose, dextrin, starch, microcrystalline cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose, polyethylene glycol, finely-divided cross-linked polyvinylpyrrolidone and a mixture thereof.
7 . The fused solid dispersion of claim 4 , wherein the sugar alcohol is selected from the group consisting of xylitol, sorbitol, mannitol and a mixture thereof.
8 . The fused solid dispersion of claim 4 , wherein the water soluble polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide, polyvinyl alcohol and a mixture thereof.
9 . The fused solid dispersion of claim 4 , wherein the oily base is selected from the group consisting of sucrose fatty acid ester, glyceryl behenate, glyceryl palmitostearate, glyceryl monooleate, glyceryl monostearate and a mixture thereof.
10 . A tablet for oral administration comprising the fused solid dispersion according to claim 1 .
11 . The tablet for oral administration of claim 10 , which is a controlled release tablet comprising the fused solid dispersion and a release-controlling agent for the slow release of the active ingredient.
12 . The tablet for oral administration of claim 11 , which further comprises a pharmaceutically acceptable excipient.
13 . The tablet for oral administration of claim 12 , which comprises the fused solid dispersion, the release-controlling agent and the pharmaceutically acceptable excipient in a weight ratio ranging from 1:0.01˜3:0˜3.
14 . The tablet for oral administration of claim 10 , which is a multilayer tablet consisting of a rapid release layer comprising the fused solid dispersion and the pharmaceutically acceptable excipient, and a controlled release layer comprising the fused solid dispersion and a release-controlling agent.
15 . The tablet for oral administration of claim 11 , wherein the release-controlling agent is selected from the group consisting of polyethylene oxide having a molecular weight ranging from 10,000 to 9,000,000, hydroxypropylmethyl cellulose having a molecular weight ranging from 1,000 to 4,000,000, hydroxypropyl cellulose, carboxyvinyl polymer, polyvinyl alcohol, xanthan gum, guar gum, locust bean gum, carboxymethyl cellulose and its derivative, methyl cellulose and its derivative, and povidone-polyvinylacetate copolymer having a molecular weight ranging from 2,000 to 2,000,000.
16 . The tablet for oral administration of claim 14 , wherein the controlled release layer further comprises a pharmaceutically acceptable excipient.
17 . The tablet for oral administration of claim 12 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a cross-linked polyvinylpyrrolidone, a cross-linked sodium carboxymethyl cellulose, carboxymethyl starch, calcium methacrylate-divinylbenzene copolymer, polyvinyl alcohol, lactose, microcrystalline cellulose and cellulose derivative, starch and its derivative, cyclodextrin and dextrin derivative, pregelatinized starch and its derivative, colloidal silica, magnesium stearate, glyceryl monostearate, sodium stearyl fumarate, and hydrogenated caster oil.
18 . The tablet for oral administration of claim 14 , wherein the rapid release layer comprises the fused solid dispersion and the pharmaceutically acceptable excipient in a weight ratio ranging from 1:0.05 to 1:3.
19 . The tablet for oral administration of claim 16 , wherein the controlled release layer comprises the fused solid dispersion, the release-controlling agent and the pharmaceutically acceptable excipient in a weight ratio ranging from 1:0.01˜3:0˜3.
20 . A process for preparing the tablet for oral administration of claim 10 comprising:
(a) heating to melt an active ingredient having a melting point of 80° C. or below and adding a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 m 2 /g thereto to obtain a homogenous fused solid dispersion;
(b) cooling, drying and pulverizing the fused solid dispersion obtained in step (a) to obtain granules; and
(c) adding a release-controlling agent or a pharmaceutically acceptable excipient to the granules obtained in step (b) and compressing the resulting mixture into a tablet.
21 . The process of claim 20 , which further comprises the step of adding a tabletting aid selected from the group consisting of a sugar alcohol, a water soluble polymer, an oily base and a mixture thereof, when adding the pharmaceutically acceptable absorbent in step (a).
22 . The tablet for oral administration of claim 14 , wherein the release-controlling agent is selected from the group consisting of polyethylene oxide having a molecular weight ranging from 10,000 to 9,000,000, hydroxypropylmethyl cellulose having a molecular weight ranging from 1,000 to 4,000,000, hydroxypropyl cellulose, carboxyvinyl polymer, polyvinyl alcohol, xanthan gum, guar gum, locust bean gum, carboxymethyl cellulose and its derivative, methyl cellulose and its derivative, and povidone-polyvinylacetate copolymer having a molecular weight ranging from 2,000 to 2,000,000.
23 . The tablet for oral administration of claim 14 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a cross-linked polyvinylpyrrolidone, a cross-linked sodium carboxymethyl cellulose, carboxymethyl starch, calcium methacrylate-divinylbenzene copolymer, polyvinyl alcohol, lactose, microcrystalline cellulose and cellulose derivative, starch and its derivative, cyclodextrin and dextrin derivative, pregelatinized starch and its derivative, colloidal silica, magnesium stearate, glyceryl monostearate, sodium stearyl fumarate, and hydrogenated caster oil.
24 . The tablet for oral administration of claim 16 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a cross-linked polyvinylpyrrolidone, a cross-linked sodium carboxymethyl cellulose, carboxymethyl starch, calcium methacrylate-divinylbenzene copolymer, polyvinyl alcohol, lactose, microcrystalline cellulose and cellulose derivative, starch and its derivative, cyclodextrin and dextrin derivative, pregelatinized starch and its derivative, colloidal silica, magnesium stearate, glyceryl monostearate, sodium stearyl fumarate, and hydrogenated caster oil.